Abstract
We previously reported the prognostic factors that can be identified at the onset of acute lymphoid leukemia (ALL) [8]. The factors defining the prognosis are, according to our experience: the WHO Reference Center cytologic types (the “prolympho- blastic” type being always poor, the “microlymphoblastic” type good, and the “macrolymphoblastic” and the “prolymphocyte” intermediate [8]); the T-type is always poor, the null, as they were only characterized in our preceding protocols, intermediate [1]; and, in the cases of those above “intermediate” prognosis types, the volume (V) of the neoplasia plays a prognostic role, i.e., V+ (³ 104leukemic cells/mm3) and/or significant clinical masses suggest a poor prognosis [8].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Belpomme D, Mathé G, Davies AJS (1977) Clinical significance and prognostic value of the T-B immunological classification of human primary acute lymphoid leukaemias. Lancet 1:555–558.
Bernard J, Boiron M, Jacquillat C, Weil M, Najean Y (1966) Un nouvel agent actif dans le traitement des leucémies aiguës: La cytosine arabinoside. Presse Med 74:799–802
Florentin I, Kiger N, Bruley-Rosset M, Schulz J, Mathé G (1978) Effect of seven immunomodulators on different types of immune responses in mice. In: Serrou B, Rosenfeld C (eds) Human lymphocyte differntiation: Its application to cancer. Elsevier/North-Holland, Biomedical Press, Amsterdam, pp 299–304
Florentin I, Schulz J, Bruley-Rosset M, Kiger N, Mathé G (1980) In vivo immunomo- dulating properties of two synthetic agents: Azimexon and tuftsin. In: Mathé G, Muggia F (eds) Cancer chemo- and immunopharmacology. II. Immunopharmacology, relations and general problems. Springer, Berlin Heidelberg New York
Goutner A, Schwarzenberg L, Mathé G (1980) Phase I study of Azimexon in immunodepressed cancer patients. In: Second International Conference: Immunotherapy of cancer, present status of trials in man, Bethesda, xx April 1980
Mathé G, Schweisguth O, Brule G, Schneider M, Amiel JL, Schwarzenberg L, Cattan A (1963) Essai de traitement par la cyclophosphamide de la leucémie lymphoblastique aiguë et du lymphoblastosarcome. Presse Med 71:402–404
Mathé G, Amiel JL, Hayat M et al. (1970) Adriamycin in the treatment of acute leukemias. In: Mathé G (ed) Advances in the treatment of acute (blastic) leukemias. Springer, Berlin Heidelberg New York, pp 168–172
Mathé G, de Vassal F, Delgado M et al. (1976) 1975 current results of the first 100 cytologically typed acute lymphoid leukemia submitted to BCG active immunotherapy. Cancer Immunol Immunother 1:77–86
Mathé G, de Vassal F, Schwarzenberg L et al. (1978) Preliminary results of three protocols for the treatment of acute lymphoid leukaemia of children: Distinction of two groups of patients according to predictable prognosis. Med Pediatr Oncol 4:17–27
Mathé G, Misset JL, de Vassal.F et al. (1978) Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma and Hodgkin’s disease: Absence of crossresistance with vincristine. Cancer Treat Rep 62:805–809
Mathé G, Misset JL, Gil-Delgado M, Delgado M, de Vassal F (1978) Leukemic (or stage V) lymphosarcoma. In: Mathé G, Seligmann M, Tubiana M (eds) Lymphoid neoplasias II: Clinical and therapeutic aspects. Springer, Berlin Heidelberg New York, pp 88–107
Misset JL, de Vassal F, Jasmin C, Mathé G (to be published) Neuroprophylaxis in acute lymphoblastic leukemia. Correlation of neurological risk and efficacy of prevention with other prognostic factors. Eur J Cancer
Schaison G, Harousseau JL, Jacquillat C, Weil M, Bernard J (1979) Phase I treatment protocol for children with increased risk acute lymphocytic leukemia (IRALL). Proc Am Assoc Cancer Res 20:104
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Misset, J.L. et al. (1982). An Intensive Chemo- or Chemoimmunotherapy Regimen for Patients with Intermediate and Poor-Prognosis Acute Lymphatic Leukemia and Leukemic Lymphoblastic Lymphosarcoma: Preliminary Results with 14-Month Median Follow-Up. In: Mathé, G., Bonadonna, G., Salmon, S. (eds) Adjuvant Therapies of Cancer. Recent Results in Cancer Research, vol 80. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81685-7_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-81685-7_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81687-1
Online ISBN: 978-3-642-81685-7
eBook Packages: Springer Book Archive